VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
426
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $117K | 0.06% |
4,761
-7,502
| -61% | -$185K |
|
427
Codexis
CDXS
$218M
| $117K | 0.06% |
25,102
+13,323
| +113% | +$62.1K |
|
428
Inovio Pharmaceuticals
INO
$143M
| $117K | 0.06% |
6,242
+197
| +3% | +$3.69K |
|
429
Mersana Therapeutics
MRSN
$34.7M
| $115K | 0.06% |
785
-617
| -44% | -$90.4K |
|
430
Nkarta
NKTX
$151M
| $115K | 0.06% |
19,135
+10,559
| +123% | +$63.2K |
|
431
Allogene Therapeutics
ALLO
$251M
| $114K | 0.06% |
18,097
+6,635
| +58% | +$41.7K |
|
432
CRISPR Therapeutics
CRSP
$4.77B
| $113K | 0.06% |
2,791
+996
| +55% | +$40.5K |
|
433
Blackstone Secured Lending
BXSL
$6.71B
| $112K | 0.06% |
5,029
+353
| +8% | +$7.89K |
|
|
CMPS
434
Compass Pathways
CMPS
$472M
| $112K | 0.06% |
13,896
+2,835
| +26% | +$22.8K |
|
|
SRNE
435
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $111K | 0.06% |
125,062
+50,975
| +69% | +$45.2K |
|
436
Caribou Biosciences
CRBU
$169M
| $108K | 0.06% |
17,165
-3,204
| -16% | -$20.1K |
|
|
KLRS
437
Kalaris Therapeutics, Inc. Common Stock
KLRS
$87.9M
| $107K | 0.06% |
+909
| New | +$107K |
|
438
ImmunityBio
IBRX
$2.25B
| $105K | 0.06% |
20,782
-14,266
| -41% | -$72.3K |
|
439
C4 Therapeutics
CCCC
$191M
| $101K | 0.05% |
17,102
-2,203
| -11% | -$13K |
|
440
Cassava Sciences
SAVA
$104M
| $93.8K | 0.05% |
3,175
-1,092
| -26% | -$32.3K |
|
441
Fate Therapeutics
FATE
$111M
| $92K | 0.05% |
9,113
+3,506
| +63% | +$35.4K |
|
442
Arcus Biosciences
RCUS
$1.23B
| $86.2K | 0.05% |
4,166
-902
| -18% | -$18.7K |
|
443
Novavax
NVAX
$1.25B
| $83.6K | 0.04% |
8,129
+5,436
| +202% | +$55.9K |
|
444
Blackstone
BX
$131B
| – | – |
-6,942
| Closed | -$581K |
|
445
Athira Pharma
ATHA
$15.3M
| – | – |
-13,008
| Closed | -$39K |
|
446
Berkshire Hathaway Class B
BRK.B
$1.08T
| – | – |
-2,369
| Closed | -$633K |
|
447
American International
AIG
$44.3B
| – | – |
-13,160
| Closed | -$625K |
|
448
Allstate
ALL
$53.5B
| – | – |
-5,863
| Closed | -$730K |
|
449
Amcor
AMCR
$19B
| – | – |
-53,756
| Closed | -$577K |
|
450
Advanced Micro Devices
AMD
$245B
| – | – |
-7,460
| Closed | -$473K |
|